F S&P 500
5,206.50 -6.25 (-0.12%) F Dow Jones
39,160.00 -35.00 (-0.09%) F Nasdaq
18,150.75 -35.75 (-0.20%) E-mini Russell 2000 Index Futur
2,059.60 -5.20 (-0.25%) Petróleo
79.46 +0.47 (+0.60%) Oro
2,321.20 -1.10 (-0.05%)
eFFECTOR Therapeutics, Inc. (EFTR)
Fuera de horario:
eFFECTOR Therapeutics, Inc.
142 North Cedros Avenue
Suite B
Solana Beach, CA 92075
United States
858 925 8215
https://effector.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 14
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Stephen T. Worland Ph.D. | CEO, President & Director | 873.96k | N/D | 1958 |
| Mr. Michael Byrnes M.B.A. | Chief Financial Officer | 654.82k | N/D | 1977 |
| Dr. Douglas Warner M.D. | Chief Medical Officer | 660.16k | N/D | 1972 |
| Dr. Davide Ruggero Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | N/D | N/D | N/D |
| Dr. Kevan M. Shokat Ph.D. | Co-Founder and Member of Clinical & Scientific Advisory Board | N/D | N/D | N/D |
Descripción
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Gestión corporativa
La calificación ISS Governance QuickScore de eFFECTOR Therapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
